Axsome Therapeutics, Inc. AXSM
We take great care to ensure that the data presented and summarized in this overview for Axsome Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding AXSM
View all-
Rtw Investments, LP New York, NY4.05MShares$480 Million5.59% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.9MShares$463 Million0.01% of portfolio
-
Black Rock Inc. New York, NY3.3MShares$391 Million0.01% of portfolio
-
Fairmount Funds Management LLC Philadelphia, PA1.47MShares$174 Million24.98% of portfolio
-
Bvf Inc San Francisco, CA1.39MShares$165 Million4.4% of portfolio
-
Ra Capital Management, L.P. Boston, MA1MShares$119 Million1.37% of portfolio
-
Macquarie Group LTD Australia, C3964KShares$114 Million0.09% of portfolio
-
State Street Corp Boston, MA947KShares$112 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA913KShares$108 Million0.01% of portfolio
-
Eventide Asset Management, LLC Boston, MA829KShares$98.2 Million1.34% of portfolio
Latest Institutional Activity in AXSM
Top Purchases
Top Sells
About AXSM
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. It is also developing AXS-07, a novel, oral, rapidly absorbed, multi-mechanistic, and investigational medicine that has completed two Phase III trials for the acute treatment of migraine; AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is in Phase III trial to treat narcolepsy; and AXS-14, a novel, oral, and investigational medicine that is in Phase III trial for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.
Insider Transactions at AXSM
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 14
2025
|
Nick Pizzie Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,000
-6.64%
|
$393,000
$131.07 P/Share
|
|
Feb 14
2025
|
Nick Pizzie Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,000
+6.23%
|
$9,000
$3.5 P/Share
|
|
Feb 13
2025
|
Nick Pizzie Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
12,000
-22.15%
|
$1,548,000
$129.86 P/Share
|
|
Feb 13
2025
|
Nick Pizzie Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,000
+18.13%
|
$36,000
$3.5 P/Share
|
|
Jan 03
2025
|
Mark Coleman |
BUY
Exercise of conversion of derivative security
|
Direct |
9,127
+13.77%
|
$82,143
$9.0 P/Share
|
|
Nov 19
2024
|
Mark Coleman |
BUY
Exercise of conversion of derivative security
|
Direct |
33,410
+41.03%
|
$167,050
$5.94 P/Share
|
|
Sep 11
2024
|
Mark E Saad |
SELL
Open market or private sale
|
Direct |
11,016
-52.41%
|
$1,002,456
$91.31 P/Share
|
|
Sep 11
2024
|
Mark E Saad |
BUY
Exercise of conversion of derivative security
|
Direct |
11,016
+34.39%
|
$33,048
$3.67 P/Share
|
|
Aug 09
2024
|
Mark L. Jacobson Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
47,739
-89.2%
|
$4,010,076
$84.26 P/Share
|
|
Aug 09
2024
|
Mark L. Jacobson Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
47,739
+47.14%
|
$190,956
$4.04 P/Share
|
|
May 29
2024
|
Mark Coleman |
SELL
Open market or private sale
|
Direct |
5,248
-26.44%
|
$393,600
$75.14 P/Share
|
|
May 29
2024
|
Mark L. Jacobson Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
7,910
-57.77%
|
$585,340
$74.31 P/Share
|
|
May 29
2024
|
Mark L. Jacobson Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
13,693
+50.0%
|
$13,693
$1.3 P/Share
|
|
May 28
2024
|
Mark Coleman |
SELL
Open market or private sale
|
Direct |
5,249
-20.91%
|
$393,675
$75.21 P/Share
|
|
Apr 01
2024
|
Mark L. Jacobson Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
24,662
-100.0%
|
$1,898,974
$77.24 P/Share
|
|
Apr 01
2024
|
Mark L. Jacobson Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
24,662
+50.0%
|
$24,662
$1.3 P/Share
|
|
Mar 15
2024
|
Roger Jeffs |
SELL
Open market or private sale
|
Direct |
2,347
-1.91%
|
$166,637
$71.61 P/Share
|
|
Mar 15
2024
|
Roger Jeffs |
BUY
Exercise of conversion of derivative security
|
Direct |
2,347
+1.87%
|
$68,063
$29.91 P/Share
|
|
Mar 14
2024
|
Roger Jeffs |
SELL
Open market or private sale
|
Direct |
29,976
-11.02%
|
$2,068,344
$69.7 P/Share
|
|
Mar 14
2024
|
Roger Jeffs |
BUY
Exercise of conversion of derivative security
|
Direct |
29,976
+9.92%
|
$689,448
$23.78 P/Share
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 130K shares |
|---|
| Open market or private sale | 92.2K shares |
|---|